Age-related macular degeneration (AMD)
pharmacologic vitreodynamics 34
submacular hemorrhage, see Submacular hemorrhage
Alkylphosphocholines (APCs), proliferative
vitreoretinopathy management
in vitro effects 50
in vivo studies 50–53
mechanism of action 49, 50
overview 46
prospects 53
structures 49
Anomalous posterior vitreous detachment 23
Bevacizumab, diabetic retinopathy
management 74, 75
Brain-derived neurotrophic factor (BDNF)
diabetic retinopathy dysfunction 64
retinal neuron maintenance 61
Chondroitinase, enzymatic vitreolysis 17
Ciliary neurotrophic factor (CNTF),
neuroprotection in diabetic retinopathy 65
Collagen
types in vitreous humor 8–11, 21
vitreoretinal adhesion role 13
Dexamethasone, intravitreal injection for
diabetic retinopathy 76
Diabetic macular edema (DME),
pharmacologically-assisted vitrectomy 78
Diabetic retinopathy (DR)
corticosteroid intravitreal injection therapy
dexamethasone 76
pharmacologically assisted vitrectomy
78, 79
triancinolone acetonide 75, 76
defects in retinal neuron maintenance
blood-retina barrier 61, 62
glucose transporters 62
glutamate metabolism 62
neurotrophins 62–64
epidemiology 69
neuroprotection
neurodegeneration evidence 57
overview 56
prospects 65, 66
retinal neuron maintenance
blood-retina barrier 57, 58
excitatory neurotransmitters 59
metabolite delivery 58
neurotrophins 59–61
strategies
insulin 64, 65
pentazocine 65
retinal glucose metabolism control
64
pars plana vitrectomy
high-speed cutters 77
pharmacologically-assisted vitrectomy
78, 79
small-gauge vitrectomy 78
techniques 76, 77
vitreous base cleaning 77, 78
pathogenesis
chemical diffusion theory 70, 71
mechanical release theory 70
oxygenation hypothesis 71, 72
vascular endothelial growth factor 33,
34, 71
vascular endothelial growth factor
inhibition therapy
bevacizumab 74, 75
pegaptanib 74
Diabetic retinopathy (DR) (continued)
pharmacologically assisted vitrectomy 78, 79
ranibizumab 75
rationale 71, 72
Dispase, enzymatic vitreolysis 17
Erythropoietin (EPO)
diabetic retinopathy dysfunction 63
retinal neuron maintenance 60
5-Fluorouracil, proliferative vitreoretinopathy management 48
Glucose transporters (GLUTs)
diabetic retinopathy dysfunction 62
retinal neuron maintenance 58
Glycosoaminoglycans (GAGs), vitreous humor 8, 11
Growth-associated protein-43 (GAP-43), upregulation in proliferative vitreoretinopathy 43
Hepatocyte growth factor (HGF), retinopathy of prematurity levels 90
Hyaluronan, vitreous humor 11, 12, 21
Hyaluronidase
enzymatic vitreolysis 17, 23, 24
vitrase trials 24
Inner limiting lamina (ILL), vitreoretinal adhesion 12, 26
Insulin
diabetic retinopathy dysfunction 63
neuroprotection in diabetic retinopathy 64, 65
retinal neuron maintenance 60
Insulin-like growth factor-1 (IGF1)
diabetic retinopathy dysfunction 63, 64
retinal neuron maintenance 60, 61
Internal limiting membrane (ILM), remnants and removal 2–4
Microplasmin, enzymatic vitreolysis 15, 16, 28–30
Müller cell, hypertrophy in retinal detachment 41, 42, 47
Neuroprotection, see Diabetic retinopathy
Opticin, vitreoretinal adhesion role 13
Oxygen, vitreous cavity levels after vitrectomy 5, 32–34
Pars plana vitrectomy (PPV), diabetic retinopathy
high-speed cutters 77
pharmacologically-assisted vitrectomy 78, 79
small-gauge vitrectomy 78
techniques 76, 77
vitreous base cleaning 77, 78
Pegaptanib
diabetic retinopathy management 74
retinopathy of prematurity inhibition management 91–96
Pentazocine, neuroprotection in diabetic retinopathy 65
Pharmacologic vitreolysis
enzymatic vitreolysis
chondroitinase 17
dispase 17
hyaluronidase 17, 23, 24
microplasmin 15, 16, 28–30
plasmin 15, 16, 27, 28, 30
tissue plasminogen activator 16
molecular flux 32
objectives 1–5
posterior vitreous detachment 1, 7, 14, 15, 26, 31
vitreodynamics 31–34
vitreous liquefaction 1, 14
Pigment epithelium-derived factor (PEDF)
diabetic retinopathy dysfunction 64
retinal neuron maintenance 61
Plasmin, enzymatic vitreolysis 15, 16, 27, 28, 30
Posterior vitreous detachment (PVD)
anomalous posterior vitreous detachment 23
pharmacologic vitreolysis 1, 7, 14, 15, 26, 31
vitreous cavity oxygen levels after vitrectomy 5, 32–34
Proliferative vitreoretinopathy (PVR)
alkylphosphocholine therapy
in vitro effects 50
in vivo studies 50–53
mechanism of action 49, 50
overview 46
prospects 53
structures 49
cell biology 47, 48
cellular changes in humans 42, 43
pharmacotherapy 48
retinal detachment response 37, 42

Ranibizumab, diabetic retinopathy
management 75
Retinal detachment, see also Proliferative
vitreoretinopathy
cell biology 47, 48
cell proliferation 41
cellular changes in humans 42, 43
Müller cell hypertrophy 41, 42, 47
photoreceptor cell death 39–41
photoreceptor outer segment and synapse
degeneration 39
retinal neuron structural remodeling 41
retinal pigment epithelium response
partial dedifferentiation 38
proliferation and migration into
subretinal space 38, 39
Retinal ganglion cell (RGC), loss in diabetic
retinopathy 57
Retinopathy of prematurity (ROP)
clinical guidelines 89
pathogenesis 89, 90
pegaptinib therapy 92–96
vitreous biochemistry 90, 91

Submacular hemorrhage
tissue plasminogen activator-assisted
vitrectomy
indications 87
outcomes 83–87
rationale 82, 83
study design 83
visual prognosis 82

Tissue plasminogen activator
assisted vitrectomy for submacular
hemorrhage
indications 87
outcomes 83–87
rationale 82, 83
study design 83
enzymatic vitreolysis 16

Transforming growth factor-β (TGF-β),
retinopathy of prematurity levels 91, 96
Triancinolone acetonide, intravitreal injection
for diabetic retinopathy 75, 76

Vascular endothelial growth factor (VEGF)
diabetic retinopathy
inhibition therapy
bevacizumab 74, 75
pegaptanib 74
pharmacologically assisted
vitrectomy 78, 79
ranibizumab 75
rationale 71, 72
response 33, 34, 63
posterior vitreous detachment response
34
retinal neuron maintenance 59, 60
retinopathy of prematurity
inhibition therapy 91–96
levels 90
Vitrase, see Hyaluronidase
Vitreolysis, see Pharmacologic vitreolysis
Vitreoretinal adhesion, mechanisms 12, 13
Vitreoretinopathy, see Proliferative
vitreoretinopathy
Vitreous humor
collagen types 8–11, 21
glycosaminoglycans 8, 11
liquefaction in pharmacologic vitreolysis 13, 14
macromolecules 8, 21
retinopathy of prematurity biochemistry 90, 91
supramolecular organization 11, 12, 21, 23